Milan - Delayed Quote EUR
Bristol-Myers Squibb Company (1BMY.MI)
42.36
-0.25
(-0.59%)
As of April 24 at 4:08:41 PM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 25 | 24 |
| Avg. Estimate | 11.31B | 11.61B | 45.9B | 42.96B |
| Low Estimate | 11.15B | 11.39B | 45.41B | 40.92B |
| High Estimate | 11.42B | 11.77B | 46.63B | 44.67B |
| Year Ago Sales | 12.2B | 11.89B | 48.3B | 45.9B |
| Sales Growth (year/est) | -7.29% | -2.39% | -4.97% | -6.40% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 1BMY.MI | -- | -- | -- | -- |
| S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/23/2025 |
| Maintains | Jefferies: Buy to Buy | 4/23/2025 |
| Initiated | Piper Sandler: Overweight | 4/22/2025 |
| Maintains | UBS: Neutral to Neutral | 4/11/2025 |
| Downgrade | Goldman Sachs: Buy to Neutral | 4/8/2025 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 2/7/2025 |